Two of the frontrunners in finding a viable medicine against COVID-19 are now able to resume their tests.
The week started with promising news from two of the companies that are working on a potential COVID-19 vaccine.
AstraZeneca and Johnson & Johnson announced that they are ready to resume the temporarily paused vaccine trials. The decision to halt the trails came after each of them reported that a volunteer got unexpectedly sick.
AstraZeneca was authorized by the US Food and Drug Administration to restart the trials after an inquiry showed that the global safety data showed that it's all safe. AstraZeneca's trial was held in September in the UK after a person developed a neurological condition.
Johnson & Johnson's trial was paused earlier this October after a participant reported an "unexpected illness." At the end of last week, JnJ stated that "no clear cause" led to the illness and that "preparations to resume the trial in the United States are now underway." No clear date was specified when the trial will resume, but according to people familiar with the matter, the event will probably occur next week.
According to government health officials and independent experts, these temporary pauses are setting an example of how safety processes work.
Read more about JnJ's situation here!
Sources: edition.cnn.com, finance.yahoo.com
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.